Open AccessPET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma
Author(s) -
Ingo Janssen,
Clara C. Chen,
Corina Millo,
Alexander Ling,
David Taïeb,
Frank I. Lin,
Karen T. Adams,
Katherine I. Wolf,
Peter Herscovitch,
Antonio Tito Fojo,
Inga Buchmann,
Electron Kebebew,
Karel Pacák
Publication year - 2016
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-016-3357-x
Subject(s) - medicine , paraganglioma , pheochromocytoma , nuclear medicine , somatostatin receptor , pet ct , positron emission tomography , radiology , confidence interval , magnetic resonance imaging , positron emission tomography computed tomography , somatostatin
Pheochromocytomas/paragangliomas (PPGLs) and their metastases are tumors that predominantly express somatostatin receptor 2 (SSR2). (68)Ga-DOTA(0)-Tyr(3)-octreotate ((68)Ga-DOTATATE) is a PET radiopharmaceutical with both high and selective affinity for SSRs. The purpose of this study was to evaluate the utility of (68)Ga-DOTATATE in comparison with other specific and nonspecific radiopharmaceuticals recommended in the current guidelines for the localization of metastatic sporadic PPGL by PET/CT.